ACT DMD Update with PTC (February 2014) On February 5, 2014, Dr. Robert Spiegel, Chief Medical Officer at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD). Research & Clinical Trial Webinars,Webinars 11 years ago You may also like 59:38 Supporting Families Through Decision Making 2 years ago Care Webinars,Webinars palliative care 52:31 Affinity Duchenne™ and Affinity Beyond™: Updates on Investigational RGX-202 from REGENXBIO 2 years ago Research & Clinical Trial Webinars,Webinars 31:23 Advocating for Access: Insurance 101 2 years ago Care Webinars,Webinars 29:12 Advocating for Access: Navigating Approved Therapies in Duchenne 2 years ago Care Webinars,Webinars 1:11:00 Webinar: ELEVIDYS Approval: What this means for you and your family 2 years ago Care Webinars,Webinars 46:01:00 Webinar: ENVISION Study Update with Sarepta Therapeutics 2 years ago Research & Clinical Trial Webinars,Webinars 37:54 Community Town Hall: SRP-9001 Advisory Committee Update (May 2023) 2 years ago Research & Clinical Trial Webinars,Webinars 55:52 Webinar: Edgewise — A Novel Approach Designed to Protect Muscle in Becker (May 2023) 2 years ago Research & Clinical Trial Webinars,Webinars «1…34567…26»Page 5 of 26